A review of comprehensive and clinically relevant data to date on TRAC dd-cfDNA
Presented by Dr. Steve Kleiboeker
The first look at potential synergies of combining TRAC dd-cfDNA and TruGraf: A Case Study Review
Presented by Dr. John Friedewald
An introduction to new study data utilizing dd-cfDNA as a reliable measurement for the effectiveness of treatment for patients with biopsy-proven antibody mediated rejection.
Presented by Dr. Saif Muhsin
Presentation of a new rejection study and how your program can be included
Presented by Dr. John Holman
"Clinical performance of a ddcfDNA assay for detection of rejection in kidney transplant recipients"
"Vira-ome: a tool for an unbiased plasma virome analysis of SOT recipients from cell-free DNA sequences"
"Rare HLA DRB1*10-DQB1*06 Linkage Disequilibrium: A case emphasizing the need of having the right HLA tools in your toolbox kit"
With decades of experience in clinical diagnostics and 3,000+ tests available, Viracor has never lost sight of the connection between the testing we perform and the patients you serve. At Viracor, your patient is so much more than a specimen.
Experience and Service You Can Trust
Viracor Eurofins was one of the first laboratories in the U.S. dedicated to serving the distinctive needs of transplant patients. We know transplant diagnostics.
As a specialty lab partnering with hundreds of academic hospitals & transplant centers, Viracor understands the complex diagnostic challenges that can occur, and your related testing needs for pre and post transplantation.
We know that accelerated, clinically meaningful results are critical to transplant patient outcomes. This is why we’re committed to bringing you fast, accurate results that can help you counter infections and minimize graft failure.
Same day results (within 24 hours or sooner from specimen receipt) for:
Powered by Transplant Genomics
The only blood test to rule out subclinical rejection in transplant patients with stable renal function, covered by CMS.
A donor-derived cell-free DNA assay that utilizes a liquid biopsy and provides healthcare professionals with actionable data — comparable to other dd-cfDNA assays on the market — for evaluating rejection in kidney transplant patients.
When rejection is not the underlying cause of symptoms, could it be an active BKV, CMV or other infection? Infectious disease investigative testing can be critical for treatment management.
Viracor has a comprehensive ID test portfolio, including COVID-19 Viral and Antibody Testing.
Immunosuppressive drugs are essential to prevent rejection, but the risk of toxicity varies due to an individual patient's metabolism, absorption and drug interactions.
Additionally, variability is observed in the pharmacokinetics of triazole antifungal drugs. By using drug level monitoring, the physician is able to individualize drug dosage to improve efficacy and reduce toxicity.
The chart to the right illustrates the intended use for our proprietary transplant rejection testing based on patient status; is their organ function stable or presenting with symptoms that point to dysfunction?
Molecular Assays Designed to Help Reduce False Negatives and Under-quantification
Viracor’s qPCR assays often target two regions within the pathogen genome, utilizing unique primer and probe sets for each target site. The driving principle behind our multiple-target assay design is that when a polymorphism occurs in one assay target, the additional sets of primers and probes for the alternate target region will still detect and accurately quantify the pathogen, and thus reduces the likelihood of under-quantification or a false negative result
Assay Refinement Helps Account for New Strains or Mutations that Might Otherwise be Missed
By utilizing nucleic acid sequence databases, each qPCR assay is regularly assessed to verify that new pathogen strains or genetic polymorphisms that arise will not lead to a false negative result. If a new pathogen strain or genetic polymorphism is identified, our current assay is refined and revalidated to ensure that accurate test results are always reported.
Viracor Eurofins designs each of our assays to account for all strains, serotypes, and clinical isolates - not just the most common ones. This is especially beneficial for immunocompromised patients who may be more likely to be infected with multiple or unusual strains.
Variety of Accepted and Validated Specimen Types Give You More Options
Not only are Viracor’s assays extremely sensitive with rapid turnaround time, but they can identify pathogens using many different types of clinical specimens, such as plasma, urine, cerebrospinal fluid, lung tissue, bone marrow aspirate, throat specimens and fecal specimens, among other fluids and tissues. By providing you more options you can determine what is best for your patient and capture localized viral presentations.
Spotlight on COVID-19 Diagnostics
In partnership with the National Kidney Registry, Viracor offers COVID-19 testing to help support the continuation of paired exchanges and transplant surgeries during the pandemic. In addition, we introduced Labs@HOME, a mobile phlebotomy service for high risk patients that need to avoid a hospital visit. No other lab can deliver the full spectrum of necessary testing and services this patient population requires, and that's why hundreds of hospitals and transplant centers trust Viracor for their clinical diagnostic needs.
Let us help you streamline transplant testing for your most critical patients.
With over 35 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor is committed to helping medical professionals, transplant teams and reference labs get results faster, when it matters most.
We would be honored to be your diagnostic testing partner. For more information and to set up an account, please click on the button below.
Connect with us